Meeting
2021 ASCO Annual Meeting
First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).
Authors
Johann S. De Bono
Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
Johann S. De Bono , Natalie Cook , Evan Y. Yu , Primo "Lucky" N. Lara Jr., Judy S. Wang , Yoshihiko Yamasaki , Ikuo Yamamiya , Ping Gao , Elizabeth Martine Calleja , Dana E. Rathkopf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT02566772
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5031)
DOI
10.1200/JCO.2021.39.15_suppl.5031
Abstract #
5031
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Dana E. Rathkopf
Poster
2023 ASCO Genitourinary Cancers Symposium
Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.
First Author: Russell Kent Pachynski
Poster
2024 ASCO Genitourinary Cancers Symposium
Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer.
First Author: Piotr Jan Wysocki
Poster
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Benedito A. Carneiro